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Abstract

Author Manuscript

In studies describing the long-term follow-up up of youth at clinical high risk (CHR) of psychosis,
little attention has been given to details of specific prodromal symptoms. In this paper we describe
the prodromal symptoms of 764 CHR participants recruited in the multi-site North American
Prodrome Longitudinal Study (NAPLS). Symptoms were rated on the Scale of Prodromal
Symptoms (SOPS) at baseline and 6, 12, 18 and 24 month follow-ups. Clinical outcome at the 2year assessment was categorized as psychotic, prodromal progression, symptomatic or in
remission. The majority of the CHR sample (93%) met criteria for the attenuated positive
symptoms syndrome (APSS). Significant improvements in SOPS symptoms were observed
overtime. Unusual thought content, disorganized communication and overall ratings on
disorganized symptoms differentiated those who transitioned to psychosis from the other clinical
outcome groups. Suspiciousness and total positive symptoms differentiated those in remission
from the other clinical outcome groups.
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INTRODUCTION
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Interest in early detection and prevention of schizophrenia and other psychotic disorders has
led to more than a decade of work studying young people who may be at risk of developing
a psychotic illness. Several reviews and meta analyses have been published focusing on the
development of the field (Fusar-Poli et al., 2012b), clinical studies (Addington and
Heinssen, 2011), treatment outcome (Stafford et al., 2013) and conversion to psychosis
(Fusar-Poli et al., 2012a). Identifying predictors and mechanisms of conversion to psychosis
among such individuals ascertained to be in a clinical high risk (CHR) or prodromal clinical
state are critical steps in the search for preventive strategies for psychosis. Achieving these
aims requires sample sizes much larger than those typically available at a single research
centre within a reasonable time period. The majority of the studies described in the reviews
above were single site studies with small samples. However, three notably large samples
have been described in the literature, namely the Personal Assessment and Crisis Evaluation
(PACE) clinic in Melbourne Australia, the European Prediction of Psychosis Study (EPOS)
and the North American Prodrome Longitudinal Study (NAPLS).

Author Manuscript
Author Manuscript

The work from the PACE clinic (Nelson et al., 2013) describes the long term follow-up of
416 young people at CHR of psychosis that have been treated at the PACE clinic and/or
participated in one of their studies between 1993 and 2006. EPOS is a prediction study of
245 individuals meeting criteria for being at CHR of psychosis who were recruited from six
early detection outpatient centers in Germany, Finland, the Netherlands and England
(Ruhrmann et al., 2010). NAPLS is a consortium of eight programs focusing on the
psychosis prodrome in North America. The sites are located at Emory University, Harvard
University, University of Calgary in Canada, University of California at Los Angeles,
University of California at San Diego, University of North Carolina at Chapel Hill, Yale
University, and Zucker Hillside Hospital. In the first phase of the NAPLS project (NAPLS
1), these sites collaborated to combine previously collected datasets and produced a series of
analyses on predictors of psychosis in a sample of 291 CHR participants followed
longitudinally (Addington et al., 2007). Results of these analyses indicated that risk for the
onset of psychosis in this population was 35% after 2 ½ years of follow-up, with a
decelerating rate of conversion over this period. The NAPLS 1 data set was used to derive a
psychosis prediction algorithm with high positive predictive power (~80%), but only modest
sensitivity (~40%) (Cannon et al., 2008). The published prediction algorithm included
genetic risk (having a first degree relative with a psychotic disorder and functional decline),
more severe unusual thought content, and greater social impairment.
This first project from the NAPLS group resulted in a six year prospective study “Predictors
and Mechanisms of Conversion to Psychosis”, funded by NIMH in 2008, and described as
NAPLS 2 that included all eight NAPLS sites. The sample size of NAPLS 2 is anticipated to
be sufficient to address fundamental questions about the neurobiological correlates of the
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development of psychosis. The project has recruited a sample of 764 CHR participants and
280 healthy controls, making it the largest study of individuals at CHR of psychosis to date.
The overall methodology of NAPLS 2 and a description of the ascertainment and
demographics has been described in detail elsewhere (Addington et al., 2012). Assessment
areas for NAPLS 2 include psychopathology, early risk factors, social functioning, social
cognition, neuropsychology, treatment monitoring, neuroimaging, electrophysiology, stress
and hormones and genomics (Addington et al., 2012). Interestingly, despite the fact that
individuals at CHR of psychosis are identified on the basis of clinical symptoms, i.e. the five
attenuated positive symptoms from the Scale of Prodromal Symptoms (SOPS), little has
been published about these prodromal symptoms, particularly individual symptoms. Thus,
the focus of this paper will be on the prodromal symptoms.

Author Manuscript

Several studies have reported on the severity of attenuated psychotic symptoms. The EPOS
study (Ruhrmann et al., 2010) reported that at baseline, the SOPS negative symptoms were
rated with the greatest severity, followed by SOPS positive, general and disorganization
symptoms, a finding supported elsewhere (Comparelli et al., 2014;Fulford et al., 2014;Lee et
al., 2014;Velthorst et al., 2009). Findings from NAPLS 1 (Piskulic et al., 2012) indicated
that for 138 participants at CHR of psychosis, 82% presented with moderate severity (i.e.
score of 4 on the SOPS) or greater on at least one negative symptom. Moreover, after 12
months, these symptoms remained in the above moderate severity range for 54% of the
sample. Another study from NAPLS 1 (Alderman et al., 2014) reported that amongst Latino
CHR participants, positive symptoms were rated with the highest severity and that unusual
thought content was particularly prevalent. Amongst negative symptoms, social anhedonia
was the most common. Trouble with focus and attention was the most common disorganized
symptom while dysphoric mood was the most common general symptom.

Author Manuscript
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In terms of change over time, a Japanese study (Morita et al., 2014) reported similar severity
of positive and negative symptoms at baseline in a CHR sample but that after one year, 48%
of the sample showed little improvement in either positive or negative symptoms. In
contrast, findings from NAPLS 1 suggest that those at CHR of psychosis who did not
transition to psychosis over a 2.5 year period showed significant improvement in SOPS
positive and negative symptoms between baseline and one year later (Addington et al.,
2011). Lee and colleagues (Lee et al., 2014) reported that CHR participants who achieved
remission of positive symptoms at two years had lower SOPS positive symptom scores at
baseline, compared to CHR non-remitted individuals, and that SOPS positive symptom
score was a significant predictor of longer time to remission. Examination of the severity of
specific attenuated psychotic symptoms is rare. One study (Simon et al., 2009) reported that
full remission of SOPS subclinical hallucinations occurred in 54% of CHR participants and
either full or partial remission occurred in 68% of these individuals after one year in the
study.
There are even less data on the frequency of individual SOPS symptoms as well as the
timing of the onset of these attenuated psychotic symptoms in CHR individuals. A
retrospective study in patients with a first-episode of psychosis reported that attenuated
psychotic symptoms occurred on average 3.9 years before admission to a hospital for a
psychotic episode (Schultze-Lutter et al., 2010). A recent prospective study (Woodberry et
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al., 2014) reported that in a sample of 39 people at CHR for psychosis, for 23% the onset of
SOPS unusual thought content, suspiciousness or perceptual abnormalities occurred in
childhood, for 38.5% in adolescence, and for 38.5% in adulthood.
The aim of this paper is to (i) describe the extent of prodromal symptoms in the large
NAPLS2 study, (ii) examine the change over time of these symptoms and (iii) determine the
role of these early symptoms in terms of later clinical follow-up.

METHODS
Participants

Author Manuscript

NAPLS participants were help-seeking and were referred from health care providers,
educators, or social service agencies, or they self-referred in response to intensive
community education efforts. These initiatives included grand rounds, educational talks,
mailings, postings, websites and internet hits, and public service announcements. Each of
the eight sites developed extensive referral sources in their area, and routinely contacts them
personally, with mail outs, and through educational efforts. Potential participants underwent
a telephone screen. Those who screened positive were invited to an in-person eligibility and
consent evaluation.

Author Manuscript
Author Manuscript

The CHR sample met the Criteria of Prodromal Syndromes (COPS) which is based on the
Structured Interview for Prodromal Syndromes (SIPS)(McGlashan et al., 2010). The COPS
has three possible prodromal syndromes - attenuated positive symptom syndrome (APSS),
genetic risk and deterioration (GRD) and/or brief intermittent psychotic syndrome (BIPS).
APSS requires the presence of at least one attenuated positive psychotic symptom (unusual
thought content, suspiciousness, grandiose ideas, perceptual abnormalities, or disorganized
communication) of insufficient severity to meet diagnostic criteria for a psychotic disorder.
The attenuated psychotic symptom(s) has to have begun or worsened in the past year. The
GRD requires having a combination of both functional decline (at least a 30% drop in
Global Assessment of Function score over the last month as compared to 12 months ago)
and genetic risk; genetic risk refers to having either schizotypal personality disorder or a
first-degree relative with a schizophrenia spectrum disorder. The BIPS state requires the
presence of any one or more threshold positive psychotic symptoms (unusual thought
content, suspiciousness, grandiosity, perceptual abnormalities, and disorganized
communication) that are too brief to meet diagnostic criteria for psychosis. The APSS
criteria used in NAPLS 2 is similar to the more recent addition to DSM-V the Attenuated
Psychosis Syndrome (APS) which is characterized by psychotic-like symptoms that are
below threshold for full psychosis (Tsuang et al., 2013). Criteria are similar except that APS
requires that they are sufficiently distressing and disabling to the individual to lead them to
seek help. However, the very nature of recruitment for NAPLS 2 means the participants are
help-seeking.
After a comprehensive assessment that included administering the Structured Clinical
Interview for DSM-IV (SCID) (First et al., 1995) and the SIPS, vignettes were developed for
each CHR participant for the purpose of obtaining a consensus diagnosis. The attenuated
psychotic symptoms rated on the Scale of Prodromal Symptoms (SOPS) are described at
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length and include both recent and longstanding symptoms. The vignettes are written so that
raters from all other sites can review the information under each symptom category and
provide a reliable rating. Once approved at the site level, the vignette is presented on a
conference call for a consensus decision on the symptom ratings as well as the diagnosis.
The NAPLS-2 consensus call, chaired by JA, was held once a week and was attended by
members of each of the eight sites. Submitted vignettes are individually reviewed and a
consensus must be reached on each symptom rating, diagnosis and ultimate admission into
the study. It was often challenging making differentiations with respect to some of the
exclusion criteria listed below, but the calls were used to discuss issues such as the impact of
substance abuse and use of antipsychotics.

Author Manuscript

Cross-site reliability in the ratings of the SOPS was conducted on an annual basis using a
new videotape each year. Ratings from all raters at all sites were compared to “gold
standard” ratings on the SOPS. Intraclass correlations, over four years, for the total SOPS
scores ranged from 0.82 to 0.93 and for the attenuated positive symptom score from the
SOPS ranged from 0.92 to 0.96. There were minimal differences across the individual sites.
All intraclass correlations were in the excellent range.
Inclusion and exclusion criteria

Author Manuscript

Individuals at CHR had to be between 12 and 35 years old and meet diagnostic criteria for a
prodromal syndrome as per the COPS criteria (McGlashan et al., 2010), or if under 19, meet
criteria for schizotypal personality disorder (SPD). Participants were excluded if they met
criteria for current or lifetime Axis I psychotic disorder, including affective psychoses, IQ <
70, or had a past history of a central nervous system disorder, substance dependence in the
past 6 months, or if the diagnostic prodromal symptoms were clearly caused by an Axis I
disorder. Other non-psychotic DSM-IV disorders were not exclusionary (e.g., substance
abuse disorder, major depression, anxiety disorders, Axis II disorders), as long as the
disorder did not account for the individual's prodromal symptoms. Use of antipsychotics was
not an exclusion provided there was clear evidence that prodromal (but not psychotic)
symptoms were present when the medication was started. Control subjects could not meet
criteria for any prodromal syndrome, any current or past psychotic disorder or a Cluster A
personality disorder diagnosis, and could not have a family history (in first-degree relatives)
of any psychotic disorder or any other disorder involving psychotic symptoms. They could
not be currently using psychotropic medication.
Measures

Author Manuscript

The SCID (First et al., 1998) was used to rule out the presence of psychosis. The SIPS and
the SOPS were used to assess COPS criteria and severity of attenuated positive symptoms
and negative symptoms.
The SOPS is a 19-item scale designed to measure the severity of prodromal symptoms. The
SOPS contains four subscales for Positive, Negative, Disorganization and General
Symptoms. The five positive symptoms are P1-unusual thought content/delusional ideas,
P2-suspiciousness/persecutory ideas, P3-grandiose ideas, P4-perceptual abnormalities, P5disorganized communication. The six negative symptoms are N1-social anhedonia, N2-
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avolition, N3-expression of emotion, N4-experience of emotion and self, N5-ideational
richness, N6-occupational functioning. The four disorganization symptoms are D1-odd
behavior or appearance, D2-bizarre thinking, D3- trouble with focus and attention, D4impairment in personal hygiene. The four general symptoms are G1-sleep disturbance, G2dysphoric mood, G3-motor disturbances, G4-impaired tolerance to normal stress. Positive
symptoms are rated from 0 (absent) to 6 (severe/psychotic). Negative, disorganized and
general symptoms are rated from 0 (absent) to 6 (extreme).

Author Manuscript

Clinical outcome at each follow-up assessment was determined in the following way: (i)
remission (remission from all syndromes which means scores of 2 or less on all five positive
symptoms on the SOPS scale, or for those who have only GRD, “in remission” will require
GAF to have returned to 90% of previous best GAF.); (ii) symptomatic (not currently
meeting criteria for a prodromal risk syndrome but having ratings of 3-5 on any one of the
five positive symptoms on the SOPS, or with the no change in the GAF); (iii) prodromal
progression (currently meeting criteria for one of the at risk syndromes; APSS, GRD, BIPS)
and (iv) psychotic (currently meeting criteria for a psychotic disorder or evidencing scores
of 6 on one or more positive symptoms of the SOPS).
Transition to psychosis was determined by meeting the Presence of Psychotic Symptoms
(POPS) (Miller et al, 2003) criteria. Transition criteria is that at least one of the five SOPS
positive symptoms reached a psychotic level of intensity (rated 6) for a frequency of ≥ 1
hour per day for 4 days per week during the past month or that symptoms seriously impacted
functioning (e.g., severely disorganised or dangerous to self or others).
Statistical Analysis

Author Manuscript

Chi-square and t-tests were used to compare groups on demographics. One-way ANOVAs
were used to compare the different clinical outcome groups on prodromal symptoms. To
accommodate missing data and account for intra-participant correlation over time, the
generalized linear mixed model for repeated measures was used for the whole CHR sample
to examine changes over time (baseline, 6 months, 12 months, 18 months and 24 months)
for the five positive symptoms, the six negative symptoms and the total sub-scores for
positive, negative, disorganized and general symptoms on the SOPS for those at CHR.

RESULTS
Sample Characteristics

Author Manuscript

The sample consisted of 280 individuals in the control group (141 males and 139 females)
and 764 in the CHR group (436 males and 328 females). The controls (HC) were
significantly older than the CHR group (19.7 versus 18.5 years), and had significantly more
years of education (12.7 years versus 11.3 years). The groups did not differ in ethnicity, with
the majority being white (CHR 62.6%, HC 59.6%) or marital status with the majority being
single (95%) or living at home (CHR 75.9%, HC 63.2%) or enrolled as a student (CHR
82.3%, HC 81.1%). Significantly more of the controls were working (46.1% vs 25%). These
details are presented in Table 1. In addition the majority of all participants were born in the
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USA or Canada. Eighty percent of CHR and 93% of control participants had English as their
first language. Spanish was the first language of 50% of the non-English speaking group.
Of the total CHR sample, 93 (12.2%) transitioned to a psychotic disorder, 151 (19.8%) did
not have any follow-up, 87 (11.4%) had only the 6-month follow-up, 103 (13.4%) were only
followed to 12 months, 56 (7.3%) to 18 months and 274 (36.9%) completed a two year
follow-up. Ninety-three of 764 cases converted to psychosis, with a mean ± SD time to
conversion of 288.3 ± 287.1 days since the baseline evaluation. However eight of the cases
converted after the final 24 month follow-up.
Clinical presentation

Author Manuscript

The majority of the CHR sample (92.0%) met criteria for the attenuated positive symptoms
syndrome, either alone (83.9%) or in combination. A small proportion met other criteria.
This information is presented in Table 2.
The mean age at the presentation of the first attenuated psychotic symptom was 16.3 years,
(SD=4.60, median =15.5 years). These data were available for 674 CHR participants in the
sample. The mean length of time since the appearance of the first positive symptom was
792.7 days (SD = 950.5, median=365.5 days, range=16 days to 19 years).

Author Manuscript

The means and standard deviations of all 19 SOPS symptoms are presented in Table 3. The
most common positive symptoms were unusual thought content and perceptual
abnormalities. For negative symptoms this ranged from 56.4% endorsing poor functioning to
19.4% endorsing decreased ideational richness. Apart from “trouble with focus and
attention” disorganization symptoms were infrequently endorsed. With the exception of
impaired tolerance to normal stress, approximately 50% endorsed each of the general
symptoms. See Table 3.
Change in symptoms over time
Results of the mixed-effect models demonstrated that overall, there were significant
improvements in all 19 SOPS symptoms at each follow-up time point compared with
baseline. Although most of the clinical improvement occurred in the first 6 months, there
was still significant continued improvement occurring between 6 and 12 months for P1, P4,
positive total, N1, negative total and D2 symptoms and between 12 and 18 months for P1,
P2, P4, P5, positive total, N4, N5, D2, D3 symptoms. There were continued improvements
from 12 to 18 or 12 to 24 months for all positive symptoms except P3, N1, N3, N5, N6, D2
and D3. However, there were no significant improvements in any SOPS symptoms between
18 and 24 months.

Author Manuscript

Clinical Outcome
Since 52% of the sample was not available at the 2-year outcome, we examined clinical
outcome in two ways. First, for the 48% that either completed two years or converted and
secondly as a last observation carried forward (LOCF). These numbers are presented in
Table 4.
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For the group that reached two years, the smallest subgroup comprised those who continued
to meet prodromal progression. For the group using the LOCF, the subgroups were quite
even with the psychotic subgroup being the smallest.

Author Manuscript

Using the LOCF, the clinical outcome groups varied on the following baseline symptoms:
P1-unusual thought content (F=8.89, p<0.001), P2-suspiciousness (F=11.67, p<0.001), P5disorganization (F=6.31, p<0.001), N2-avolition (F=2.85, p<0.05), positive symptom total
score (F=12.77, p<0.001), and disorganization total score (F=6.96, p<0.001). There were no
differences for P3 (grandiosity) , P4 (perceptual abnormalities), or any of the negative
symptoms with the exception of N2 (anhedonia). When restricting the analyses to include
only the subgroup with clinical outcome data at two years, ANOVA results demonstrated
that with the exception of N2, the groups differed on the same baseline symptoms: P1
(F=9.97, p<0.001), P2 (F=6.47, p<0.001), P5 (F=5.57, p<0.01), positive total (F=9.38,
p<0.001), and disorganization total (F=5.40, p<0.01). However, post hoc examinations
revealed that the intergroup differences were not always the same. These are presented in
Table 5.

DISCUSSION
The current study presents symptom data on the largest sample of adolescents and adults at
CHR of psychosis to date. In terms of demographics, CHR subjects vary little from healthy
controls, being on average younger by one year, which may account for the one year
difference in years of education, and more likely to be living at home.

Author Manuscript

More than 92% of the CHR sample met criteria for attenuated psychotic symptom syndrome
(APSS). Although 10% did present with genetic risk and deterioration (GRD), less than 5%
met only this criterion, as those who met for GRD typically also present with APSS.
Furthermore, the Brief Intermittent Psychotic symptom criterion (BIPS) rarely occurred on
its own (n=6 cases, 0.8%). More frequently, we saw individuals who presented with APSS
but reported an occurrence of BIPS in the past three months, although that too was
infrequent (n=14 cases, 1.9%).

Author Manuscript

Next, we examined all prodromal symptoms individually. Our data support the few previous
studies that suggest that the most common symptoms at baseline are positive in that 92%
have at least one positive symptom, followed by negative and then disorganization and
general. Eighty-two percent of the sample had at least one negative symptom and 44% had
three or more negative symptoms. The most frequently endorsed positive symptoms were
unusual thought content and perceptual abnormalities, followed by suspiciousness.
Disorganized communication was infrequent and grandiosity endorsed even less often.
Avolition and poor occupational functioning were the most common negative symptoms.
None of the other symptoms were endorsed as much as unusual thought content and
perceptual abnormalities, although dysphoric mood was endorsed by 68% of the sample.
Two earlier studies have reported symptom improvement over time (Lee et al.,
2014;Addington et al., 2011). We observed that there were significant improvements in all
19 SOPS symptoms at each follow-up time point compared to baseline. Although most of
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the clinical improvement occurred in the first six months, there was still significant
continued improvement occurring between 6 and 12 months for unusual thought content,
perceptual abnormalities, anhedonia, bizarre thinking, and overall positive symptoms and
negative symptoms. Several symptoms continued to improve between 12 and 18 months,
although none improved between 18 and 24 months. Although this is only the third sample
reporting this kind of improvement it is possible that this may be the natural course over at
least the first two years. Addington et al (2011) in the NAPLS 1 sample, also considered
social functioning, and suggested that approximately one third may develop a psychotic
illness, one third may improve and one third may continue to have fluctuating attenuated
psychotic symptoms and poorer functioning. At this stage it is unclear as to the impact of
treatments on such division of CHR samples, although the NAPLS 2 project will in the near
future be able to address many questions related to the impact of treatment on the outcome
of CHR individuals.

Author Manuscript
Author Manuscript

We were also interested in when these early symptoms began. As other SOPS symptoms are
very difficult to date we focused only on the five positive symptoms. The average age of the
CHR sample was 18.6 years and they reported that they were on average 16 years old when
they were aware of the first attenuated psychotic symptom, suggesting an average of >2
years between first experiencing attenuated psychotic symptoms and seeking help. However,
this gap actually ranged from 16 days to 19 years. Thus, for some, at their baseline
assessment these attenuated psychotic symptoms are a new occurrence but for others they
have been present for much of their lives. The implication is that these individuals who have
had attenuated psychotic symptoms for many years, often since they were very young, are
not presenting until either the symptoms worsen, or they begin to impact their functioning or
they have a new attenuated psychotic symptom appearing. There is, therefore, the possibility
that some of these CHR individuals could be identified even sooner. This may be
particularly important for CHR with a long duration of symptoms as this has been shown to
be one predictor of transition to psychosis in the PACE high risk sample (Nelson et al.,
2013).

Author Manuscript

In studies of CHR, the outcome that receives the most attention is whether individuals make
the transition to psychosis. However, in NAPLS 2 we have considered whether individuals
are in remission from the attenuated psychotic symptoms or continue to present with
attenuated psychotic symptoms albeit at the same or reduced severity as baseline. We also
considered those who continue to meet criteria for at least one of the three prodromal
syndromes. Since the COPS criteria require a worsening, this group is likely to have
experienced an increase in symptoms over time, although not to the extent that they are of
psychotic intensity or may have had a remission and then a re-occurrence of symptoms. To
make the most of our data we examined outcome for those who had completed two years of
follow-up but also examined outcome using the last outcome rating conducted. What was
interesting was that although the majority of the baseline prodromal symptoms were
unrelated to later outcome some symptoms differentiated the transition group from the other
three groups, e.g., unusual thought content, disorganized communication and overall ratings
on the disorganized symptoms whereas other symptoms differentiated those in remission
from the other three groups, e.g., suspiciousness and total positive symptoms. This suggests
that the presence of certain symptoms may be typical of at risk groups regardless of whether
J Nerv Ment Dis. Author manuscript; available in PMC 2016 May 01.
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they continue to have symptoms or even make the transition to psychosis; whereas others
may be predictive of a later psychosis. Interestingly perceptual abnormalities, which was
one of the most frequently endorsed symptoms at baseline, did not relate at all to later
outcome.

Author Manuscript

One limitation of the examination of outcome is that almost 52% of the sample did not
complete 2 years. Typically it is difficult to keep young people in studies for long periods of
time, particularly in a study such as NAPLS 2 where in addition to clinical assessments
participants were also involved in assessments for biological markers; i.e. imaging, EEG,
blood draws and neurocognition. Dropping out was at times a functioning of individuals
moving away or changing schools and sites being unable to recontact people. Since most of
the young people are help-seeking and troubled by the onset of attenuated psychotic
symptoms, it is not unusual for them to no longer be interested in help once their symptoms
disappear.

Author Manuscript

In summary, our results suggest that APSS is by far the most common syndrome among
those meeting CHR COPS criteria. Positive followed by negative symptoms are the most
common, in particular, unusual thought content, perceptual abnormalities and
suspiciousness. However on average all prodromal symptoms rated on the SOPS improve
over time. For outcome groups based on clinical follow-up there are essentially three
groups: those who make the transition to psychosis, those who have a remission of
attenuated psychotic symptoms and those who continue to have attenuated psychotic
symptoms, some of whom also continue to meet prodromal criteria. Further work with this
large NAPLS sample will examine both clinical and biological predictors of psychosis. The
importance of these attenuated positive symptoms will be considered in prediction models.
However, these results suggest that more in depth study not just of those who convert but
also of those who present with attenuated psychotic symptoms and who have a complete
remission of these symptoms often within six months and of those who continue to
experience at time fluctuating subthreshold symptoms who may not go on to develop a
psychotic illness, is required. A greater understanding of those who remit may help our
understanding of psychosis and improve our identification of those who are at real risk of
developing a psychotic illness. For those who continue to experience attenuated psychotic
symptoms, further attention to interventions that may help such individuals have improved
quality of life would be the next step.
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Table 1

Author Manuscript

Differences in Demographic Characteristics between Clinical High Risk and Healthy Control Participants
Variable

Controls n = 280

Prodromal n = 764

Mean (SD)
Age in years

19.65 (4.67)

18.45 (4.23)

Years of education

12.68 (3.58)

11.28 (2.82)

Number (%)

Test Statistic

Effect Size

t

d
**

0.26

**

0.41

3.74
5.90

X2

Cramer's V

3.73

0.06

5.24

0.07

0.08

0.01

*
10.13

0.10

**

0.13

Sex
Male

141 (50.4%)

436 (57.1%)

Female

139 (49.6%)

328 (42.9%)

Author Manuscript

Race
First Nations

4 (1.4%)

13 (1.7%)

30 (10.7%)

54 (7.1%)

Black

49 (17.5%)

118 (15.5%)

Latin America/Middle East/White

167 (59.6%)

478 (62.6%)

Asian

Native Hawaiian or Pacific Islander

1 (0.4%)

3 (0.4%)

29 (10.4%)

97 (12.7%)

Yes

50 (17.9%)

142 (18.6%)

No

230 (82.1%)

621 (81.4%)

Interracial
Hispanic or Latino

Father's highest level of formal education

Author Manuscript

No or primary school
Some high school

7 (2.6%)

35 (4.9%)

High school and/or some college

13 (4.8%)

72 (10.0%)

117 (42.9%)

280 (38.9%)

136 (49.8%)

333 (46.2%)

College graduate

Mother's highest level of formal education
No or primary school

17.13

Some high school

4 (1.4%)

32 (4.3%)

High school and/or some college

8 (2.9%)

59 (7.9%)

College graduate

Author Manuscript

99 (35.6%)

283 (38.1%)

167 (60.1%)

370 (49.7%)

266 (95.0%)

720 (94.9%)

14 (5.0%)

39 (5.1%)

Marital Status
Single never married
Other

0.01

Current living arrangement
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Variable

Controls n = 280

Prodromal n = 764

Author Manuscript

Mean (SD)
Living with family

177 (63.2%)

576 (75.9%)

Living with spouse/partner

18 (6.4%)

38 (5.0%)

Living on own in apartment/house

31 (11.1%)

40 (5.3%)

4 (1.4%)

20 (2.6%)

Living in group/rooming home
Living with others, not spouse/partner

41 (14.6%)

68 (9.0%)

Living in a shelter

0 (0.0%)

2 (0.3%)

Living on the street

0 (0.0%)

0 (0.0%)

Other

9 (3.2%)

15 (2.0%)

Yes

129 (46.1%)

189 (25.0%)

No

151 (53.9%)

567 (75.0%)

Test Statistic

Effect Size

t

d
**

0.16

**

0.20

**

0.27

25.06

Currently working
42.65

Author Manuscript

Highest level of formal education obtained
High school incomplete

78.81

High school graduate

101 (36.1%)

399 (52.7%)

High school and above

92 (32.9%)

289 (38.2%)

87 (31.1%)

69 (9.1%)

Yes

227 (81.1%)

624 (82.3%)

No

53 (18.9%)

134 (17.7%)

Currently enrolled as a student
0.22

*** p<0.001

Author Manuscript

*

p<0.05

**
p<0.01

Author Manuscript
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Table 2

Author Manuscript

Frequency and Proportion of Prodromal Syndromes within the Clinical High Risk Sample.
Prodromal Criteria

Number

%

Attenuated Psychotic Symptom Syndrome (APSS)

641

83.9

Genetic Risk and Deterioration (GRD)

34

4.4

Brief Intermittent Psychotic Symptoms (BIPS)

6

0.8

Under 19 plus Schizotypal Personality Disorder

21

2.7

APSS plus GRD

48

6.3

BIPS plus APSS

12

1.6

BIPS plus APSS plus GRD

2

0.3

764

100%

Total

Author Manuscript
Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Frequency at Baseline of the Number of Clinical High Risk Participants Endorsing Each of the 19 Symptoms
on the Scale of Prodromal Symptoms (N=744)
Symptom

Mean (SD)

Number (percent) endorsing this symptom >2

Unusual thought content/delusional ideas

3.34 (1.33)

609 (79.6)

Suspiciousness/persecutory ideas

2.76 (1.51)

498 (65.1)

Grandiosity

1.00 (1.30)

121 (15.8)

Perceptual abnormalities/hallucinations

3.07 (1.50)

568 (74.2)

Disorganized communication

1.75 (1.47)

227 (29.7)

Social anhedonia

2.36 (1.74)

314 (42.3)

Avolition

2.45 (1.62)

384 (52.4)

Expression of emotion

1.36 (1.52)

188 (25.7)

Experience of emotions and self

1.75 (1.68)

283 (38.7)

Ideational richness

1.16 (1.31)

142 (19.4)

Occupational functioning

2.84 (2.01)

414 (56.4)

Odd behavior or appearance

0.84 (1.20)

94 (12.8)

Bizarre thinking

0.91 (1.20)

91 (12.4)

Trouble with focus and attention

2.64 (1.28)

434 (59.2)

Impairment in personal hygiene

0.76 (1.21)

77 (10.5)

Sleep disturbance

2.32 (1.56)

384 (52.3)

Dysphoric mood

3.34 (1.61)

507 (67.9)

Motor disturbances

0.83 (1.06)

45 (6.1)

Impaired tolerance to normal stress

2.70 (1.88)

381 (52.0)

Positive Symptoms

Negative Symptoms

Author Manuscript

Disorganization Symptoms

General Symptoms

Author Manuscript
Author Manuscript

J Nerv Ment Dis. Author manuscript; available in PMC 2016 May 01.

Addington et al.

Page 17

Table 4

Author Manuscript

Clinical Outcome of Clinical High Risk Participants at End of Study

2 YEARS
LOCF

IN REMISSION

SYMPTOMATIC

PRODROMAL PROGRESSION

PSYCHOTIC

n (%)

n (%)

n (%)

n (%)

a

93/367 (25.3%)

72/367 (19.6%)

93/367 (25.3%)

b
171/613 (27.9%)

186/613 (30.3%)

163/613 (26.6%)

93/613 (15.2%)

109/367 (29.7%)

LOCF - Last assessment carried forward
a

367 is the number of converters plus the CHR participants who completed a 2 year followup

b

613 is the number of converters plus the CHR participants who completed at least one followup

Author Manuscript
Author Manuscript
Author Manuscript
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Table 5

Author Manuscript

Post Hoc Analyses of the Baseline Differences between the Clinical Outcome Groups
BASELINE SOPS SYMPTOM
P1 - Unusual thought content

LOCF CLINICAL OUTCOME

24 MONTH CLINICAL OUTCOME

***

***

Psychotic > Remission

Psychotic > Remission

**

**

Psychotic > Symptomatic

Psychotic > Symptomatic

*
Psychotic >Prodromal Progression

**
Prodromal Progression > Remission

*
Prodromal Progression > Remission
Prodromal Progression > Symptomatic
P2 - Suspiciousness

***

Remission < Symptomatic

**

Remission < Prodromal Progression
***
Remission < Psychotic
P5 - Disorganization

***

*
**
Remission < Symptomatic
***
Remission < Psychotic

**

Psychotic > Remission

Psychotic > Remission

*

**

Psychotic >Symptomatic

Psychotic >Prodromal Progression

Author Manuscript

***
Psychotic >Prodromal Progression
N2 - Avolition
Positive total

*

NS

Remitted < Symptomatic

***

Remission < Symptomatic

Remission < Symptomatic
*

Remission < Prodromal Progression
***
Remission < Psychotic
*
Symptomatic < Psychotic
**
Prodromal Progression < Psychotic
Disorganization total

***

*

Remission < Prodromal Progression
***
Remission < Psychotic

***

Psychotic > Remission

Psychotic > Remission
**

Psychotic > Prodromal Progression
*
Psychotic > Symptomatic
LOCF=Last observation carried forward

Author Manuscript

*

p<0.05

**

**

p<0.01

***

p<0.001

Author Manuscript
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